Product Description: Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Arora M, et al. Phase 1 study of axatilimab (SNDX-6352), a CSF-1R humanized antibody, for chronic graft-versus-host disease after 2 or more lines of systemic treatment. Blood, 2020, 136: 1-2./[2]Tiessen R, et al. First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R). J Immunother Cancer, 2016, 5: P505.
CAS Number: 2155851-88-8
Molecular Weight: N/A
Compound Purity: 99.59
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: c-Fms
English
Deutsch
